Two prescription incretin medications for weight and metabolic health. Tirzepatide acts on two receptors (GIP + GLP-1); semaglutide on one (GLP-1).
Semaglutide and tirzepatide are FDA-approved prescription medications used, for appropriate patients, to support weight and metabolic health. The key mechanistic difference is receptor coverage. Both are clinical decisions requiring a provider, and both work best alongside protein, training, and sleep.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| FDA status | Approved (specific indications) | Approved (specific indications) |
| Administration | Weekly injection (and oral form exists) | Weekly injection |
| Common considerations | GI side effects; muscle loss without protein/training | GI side effects; muscle loss without protein/training |
| Foundation still matters | Yes | Yes |
Both are real tools for the right candidate, prescribed and monitored by a provider. Head-to-head response and tolerability vary by individual. Neither replaces the nutrition and training foundation that protects muscle and makes results last.
If you'd like help applying this information to your own health, schedule a consultation with the Bearing team.
Request a Consultation